Systematic Review of Antiretroviral-Associated Lipodystrophy: Lipoatrophy, but Not Central Fat Gain, Is an Antiretroviral Adverse Drug Reaction

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  de Waal, Reneé ^a   Cohen, Karen ^a   Maartens, Gary ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; DARUNAVIR PLUS RITONAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

BODY FAT DISTRIBUTION; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPOATROPHY; MONOTHERAPY; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SUBCUTANEOUS FAT; SYSTEMATIC REVIEW; WAIST HIP RATIO; WEIGHT GAIN;

ABSORPTIOMETRY, PHOTON; ADIPOSITY; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HIV PROTEASE INHIBITORS; HUMANS; INTRA-ABDOMINAL FAT; LIPODYSTROPHY; REVERSE TRANSCRIPTASE INHIBITORS; SUBCUTANEOUS FAT; TOMOGRAPHY, X-RAY COMPUTED; TORSO;

EID: 84878388296     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0063623     Document Type: Review

References (42)

1. Carr A, (2003) HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management. AIDS 17: S141-S148.
2. Grinspoon S, Carr A, (2005) Cardiovascular Risk and Body-Fat Abnormalities in HIV-Infected Adults. N Engl J Med 352: 48-62.
3. McComsey GA, Kitch D, Sax PE, Tebas P, Tierney C, et al. (2011) Peripheral and central fat changes in subjects randomized to abacavir-lamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG Study A5224s. Clin Infect Dis 53: 185-196.
4. Negredo E, Miro O, Rodriguez-Santiago B, Garrabou G, Estany C, et al. (2009) Improvement of mitochondrial toxicity in patients receiving a nucleoside reverse-transcriptase inhibitor-sparing strategy: results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA). Clin Infect Dis 49: 892-900.
5. Bachetti P, Gripshover B, Grunfeld C, Heymsfield S, McCreath H, et al. (2005) Fat Distribution in Men with HIV Infection. J Acquir Immune Defic Syndr 40: 121-131.
6. Ammassari A, Antinori A, Cozzi-Lepri A, Trotta MP, Nasti G, et al. (2002) Relationship Between HAART Adherence and Adipose Tissue Alterations. J Acquir Immune Defic Syndr 31: S140-S144.
7. Higgins JPT, Green S, (editors) (2011) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. Cochrane Handbook website. Available: www.cochrane-handbook.org. Accessed 2012 May 23.
8. Grunfeld C, Saag M, Cofrancesco J Jr, Lewis CE, Kronmal R, et al. (2010) Regional adipose tissue measured by MRI over 5 years in HIV-infected and control participants indicates persistence of HIV-associated lipoatrophy. AIDS 24: 1717-1726.
9. Kolta S, Flandre P, Van PN, Cohen-Codar I, Valantin MA, et al. (2011) Fat tissue distribution changes in HIV-infected patients treated with lopinavir/ritonavir. Results of the MONARK trial. Curr HIV Res 9: 31-39.
10. Lennox JL, Dejesus E, Berger DS, Lazzarin A, Pollard RB, et al. (2010) Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. J Acquir Immune Defic Syndr 55: 39-48.
11. Valantin MA, Flandre P, Kolta S, Duvivier C, Genin MA, et al. (2010) Fat Tissue Distribution Changes in HIV-infected Patients with Viral Suppression Treated with Darunavir/ritonavir (DRV/r) monotherapy versus 2 NRTIs + DRV/r in the MONOI-ANRS 136 Randomized Trial: Results at 48 weeks. Conference on Retroviruses and Opportunistic Infections. San Francisco.
12. van Vonderen MG, van Agtmael MA, Hassink EA, Milinkovic A, Brinkman K, et al. (2009) Zidovudine/lamivudine for HIV-1 infection contributes to limb fat loss. PLoS One 4: e5647.
13. Haubrich RH, Riddler SA, DiRienzo AG, Komarow L, Powderly WG, et al. (2009) Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS 23: 1109-1118.
14. Martinez E, Arranz JA, Podzamczer D, Lonca M, Sanz J, et al. (2009) A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression. J Acquir Immune Defic Syndr 51: 290-297.
15. McComsey G, Rightmire A, Wirtz V, Yang R, Mathew M, et al. (2009) Changes in body composition with ritonavir-boosted and unboosted atazanavir treatment in combination with Lamivudine and Stavudine: a 96-week randomized, controlled study. Clin Infect Dis 48: 1323-1326.
16. Martin A, Bloch M, Amin J, Baker D, Cooper DA, et al. (2009) Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial. Clin Infect Dis 49: 1591-1601.
17. Carr A, Ritzhaupt A, Zhang W, Zajdenverg R, Workman C, et al. (2008) Effects of boosted tipranavir and lopinavir on body composition, insulin sensitivity and adipocytokines in antiretroviral-naive adults. AIDS 22: 2313-2321.
18. Duvivier C, Ghosn J, Assoumou L, Soulie C, Peytavin G, et al. (2008) Initial therapy with nucleoside reverse transcriptase inhibitor-containing regimens is more effective than with regimens that spare them with no difference in short-term fat distribution: Hippocampe-ANRS 121 Trial. J Antimicrob Chemother 62: 797-808.
19. Cameron DW, da Silva BA, Arribas JR, Myers RA, Bellos NC, et al. (2008) A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy. J Infect Dis 198: 234-240.
20. Dube MP, Komarow L, Mulligan K, Grinspoon SK, Parker RA, et al. (2007) Long-term body fat outcomes in antiretroviral-naive participants randomized to nelfinavir or efavirenz or both plus dual nucleosides. Dual X-ray absorptiometry results from A5005s, a substudy of Adult Clinical Trials Group 384. J Acquir Immune Defic Syndr 45: 508-514.
21. Tebas P, Zhang J, Yarasheski K, Evans S, Fischl MA, et al. (2007) Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s). J Acquir Immune Defic Syndr 45: 193-200.
22. Podzamczer D, Ferrer E, Sanchez P, Gatell JM, Crespo M, et al. (2007) Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study. J Acquir Immune Defic Syndr 44: 139-147.
23. Moyle GJ, Sabin CA, Cartledge J, Johnson M, Wilkins E, et al. (2006) A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS 20: 2043-2050.
24. Jemsek JG, Arathoon E, Arlotti M, Perez C, Sosa N, et al. (2006) Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral-naive HIV-infected patients. Clin Infect Dis 42: 273-280.
25. Moyle GJ, Andrade-Villanueva J, Girard PM, Antinori A, Salvato P, et al. (2012) A randomized comparative 96-week trial of boosted atazanavir versus continued boosted protease inhibitor in HIV-1 patients with abdominal adiposity. Antivir Ther 17: 689-700.
26. Curran A, Martinez E, Saumoy M, del Rio L, Crespo M, et al. (2012) Body composition changes after switching from protease inhibitors to raltegravir: SPIRAL-LIP substudy. AIDS 26: 475-481.
27. Feeney ER, Vrouenraets SME, Wit F, Brinkman K, Capel E, et al. (2011) Switching Zidovudine to Tenofovir Improves Subcutaneous Adipose Tissue Volume and mtDNA Content. Conference on Retroviruses and Opportunistic Infections. Boston.
28. Fisher M, Moyle GJ, Shahmanesh M, Orkin C, Kingston M, et al. (2009) A randomized comparative trial of continued zidovudine/lamivudine or replacement with tenofovir disoproxil fumarate/emtricitabine in efavirenz-treated HIV-1-infected individuals. J Acquir Immune Defic Syndr 51: 562-568.
29. Valantin MA, Lanoy E, Bentata M, Kalmykova O, Boutekadjirt A, et al. (2008) Recovery of fat following a switch to nucleoside reverse transcriptase inhibitor-sparing therapy in patients with lipoatrophy: results from the 96-week randomized ANRS 108 NoNuke Trial. HIV Med 9: 625-635.
30. Carr A, Workman C, Smith DE, Hoy J, Hudson J, et al. (2002) Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. JAMA 288: 207-215.
31. Ruiz L, Negredo E, Domingo P, Paredes R, Francia E, et al. (2001) Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with hiv-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study. J Acquir Immune Defic Syndr 27: 229-236.
32. Tebas P, Zhang J, Hafner R, Tashima K, Shevitz A, et al. (2009) Peripheral and visceral fat changes following a treatment switch to a non-thymidine analogue or a nucleoside-sparing regimen in HIV-infected subjects with peripheral lipoatrophy: results of ACTG A5110. J Antimicrob Chemother 63: 998-1005.
33. Dube MP, Parker RA, Tebas P, Grinspoon SK, Zackin RA, et al. (2005) Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides. AIDS 19: 1807-1818.
34. Milinkovic A, Martinez E, Lopez S, de Lazzari E, Miro O, et al. (2007) The impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients. Antivir Ther 12: 407-415.
35. Tien PC, Benson C, Zolopa AR, Sidney S, Osmond D, et al. (2006) The Study of Fat Redistribution and Metabolic Change in HIV Infection (FRAM): Methods, Design, and Sample Characteristics. Am J Epidemiol 163: 860-869.
36. Haissman JM, Lasse SV, Sembuche S, Erikstrup C, Mmbando B, et al. (2009) Plasma Cytokine Levels in Tanzanian HIV-1-infected Adults and the Effect of Antiretroviral Treatment. J Acquir Immune Defic Syndr 52: 493-497.
37. Thoni GJ, Fedou C, Brun JF, Fabre J, Renard E, et al. (2002) Reduction of fat accumulation and lipid disorders by individualized light aerobic training in human immunodeficiency virus infected patients with lipodystrophy and/or dyslipidaemia. Diabetes Metab 28: 397-404.
38. Dolan SE, Frontera W, Librizzi J, Ljungquist K, Juan S, et al. (2006) Effects of a Supervised Home-based Aerobic and Progressive Resistance Training Regimen in Women Infected With Human Immunodeficiency Virus. A Randomized Trial. Arch Int Med 166: 1225-1231.
39. Driscoll SD, Meininger GE, Lareau MT, Dolan SE, Killilea KM, et al. (2004) Effects of exercise training and metformin on body composition and cardiovascular indices in HIV-infected patients. AIDS 18: 465-473.
40. Vlahakis SR, Bren GD, Algeciras-Schimnich A, Trushin SA, Schnepple DJ, et al. (2007) Flying in the face of resistance: antiviral-independent benefit of HIV protease inhibitors on T-cell survival. Clin Pharmacol Ther 82: 294-299.
41. Gallego-Escuredo JM, Del Mar Gutierrez M, Diaz-Delfin J, Domingo JC, Mateo MG, et al. (2010) Differential effects of efavirenz and lopinavir/ritonavir on human adipocyte differentiation, gene expression and release of adipokines and pro-inflammatory cytokines. Curr HIV Res 8: 545-553.
42. Apostolova N, Gomez-Sucerquia LJ, Gortat A, Blas-Garcia A, Esplugues JV, (2011) Compromising mitochondrial function with the antiretroviral drug efavirenz induces cell survival-promoting autophagy. Hepatology 54: 1009-1019.